Literature DB >> 18456740

Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up.

K Oberg1, S Jelic.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18456740     DOI: 10.1093/annonc/mdn116

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses.

Authors:  P Ferolla; A Faggiano; F Grimaldi; D Ferone; G Scarpelli; V Ramundo; R Severino; M C Bellucci; L M Camera; G Lombardi; G Angeletti; A Colao
Journal:  J Endocrinol Invest       Date:  2011-07-13       Impact factor: 4.256

2.  Simultaneous double thymic carcinoids: a rare initial manifestation of multiple endocrine neoplasia type 1.

Authors:  Ryutaro Kikuchi; Nobuya Mino; Taku Okamoto; Tadashi Matsukura; Takashi Hirai
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-01-12

3.  Metastatic thymic carcinoid responds to chemoradiation and octreotide: A case report.

Authors:  Zhu Mei; He Wang; Shengnan Ren; Juan Wei; Yanhong Gu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

4.  ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.

Authors:  Sk Kayum Alam; Li Wang; Yanan Ren; Christina E Hernandez; Farhad Kosari; Anja C Roden; Rendong Yang; Luke H Hoeppner
Journal:  Br J Cancer       Date:  2020-06-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.